Major Studies Evaluating Prognostic Impact of PET2 in HL
| EFS | ||||||
| Study | Year | Number of cycles | Number of patients | PET-positive | PET-negative | Follow-up (mo) |
| Hutchings et al. (12) | 2005 | 2 or 3 | 85 | 46% | 96% | 6–125 |
| Hutchings et al. (11) | 2006 | 2 | 77 | 0% | 96% | 2–41 |
| Gallamini et al. (13) | 2006 | 2 | 108 | 6% | 96% | 2–47 |
| Gallamini et al. (14*) | 2007 | 2 | 97 | 13% | 95% | 4–62 |
| Present study | 2009 | 2 | 104 | 24% | 90% | 28–40 |
| Total | 471 | 18% | 95% | |||
↵* Included only the 97 new cases.